A Study on the Safety and Efficacy of TQB3473 Tablets in the Treatment of Persistent or Chronic Primary Immune Thrombocytopenia (ITP) in Adults

This study is an extension of the TQB3473-III-01 study, aimed at evaluating the safety and efficacy of TQB3473 tablets in adult patients with persistent or chronic ITP who have received at least one ITP standard treatment that is ineffective or has recurred after treatment. This is a single arm, open label, multi cohort, multi center Phase II clinical study.

NCT Number	NCT07083739
Lead Sponsor	Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Conditions	Primary Immune Thrombocytopenia
Enrollment	320 participants
Start Date	2025-08
Primary Completion	2027-09 (estimated)
Study Completion	2028-03 (estimated)
Updated on ClinicalTrials.gov	2025-07-24